Alport Syndrome Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments
Alport Syndrome Pipeline Analysis report covers 5 drugs currently in different phases of development. Alport Syndrome is an inherited disorder involving the glomerular basement membrane of kidney. The disease is characterised by loss of kidney function, hearing loss and ophthalmic disorders. Symptoms of the disease are hematuria, nephritis, sensory deafness, Swelling throughout the body and nephropathy. The disease is classified into 3 types: X-linked Alport syndrome (XLAS), Autosomal recessive Alport syndrome (ARAS) and Autosomal dominant Alport syndrome (ADAS). Diagnoses is done using BUN and serum creatinine test, Complete blood count, Renal biopsy and Urinalysis.
The report provides Alport Syndrome treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Ember Therapeutics, Foresee Pharmaceuticals Co., Ltd., Reata Pharmaceuticals, Inc., Regulus Therapeutics Inc. and Variant Pharmaceuticals, Inc.
By Molecule Type
By Route of Administration